A patient with a large, 12cm symptomatic desmoid tumor experienced significant spontaneous regression to 3cm while on active surveillance. This challenges the common assumption that only small tumors shrink on their own, highlighting the disease's unpredictability even in severe cases.

As more effective treatments for desmoid tumors become available, a critical unmet need is emerging: knowing when to stop therapy. Future research must focus on identifying signals, such as radiologic changes on MRI, to guide treatment duration. This will help clinicians avoid both the risk of early relapse from stopping too soon and the toxicity of unnecessary overtreatment.

Desmoid tumors exhibit highly variable behavior, acting as a chronic disease in some patients while being manageable in others. This necessitates a personalized, long-term treatment strategy rather than a standard protocol, often requiring a diverse armamentarium of therapeutic options to be used over a patient's lifetime as needs change.

Desmoid tumors can shrink without treatment, a phenomenon seen in up to 35% of patients under observation. This inherent biological behavior makes it difficult to prove that continued tumor reduction during long-term therapy is solely due to the drug's effect.

The standard of care for desmoid tumors has shifted away from upfront surgery due to high recurrence rates and poor patient outcomes. Experts now recommend systemic or other local therapies first, reserving surgery only for emergencies or after careful multidisciplinary team review.

Following cryoablation, imaging of a desmoid tumor may show a paradoxical increase in size. This is often a temporary inflammatory response, not disease progression. In one case, initial swelling was followed by symptom improvement and eventual tumor shrinkage, a key finding for interpreting post-procedure scans.

Patients on niragacestat for desmoid tumors often experience rapid symptom improvement. However, this clinical benefit significantly precedes radiological response (tumor shrinkage on scans), which can take over five months to appear. This disconnect is crucial for managing patient expectations and assessing early treatment efficacy.

In a neoadjuvant cemiplimab trial, only 6% of patients had a complete response based on radiographic imaging (RECIST criteria), yet 50% achieved a pathologic complete response. This major discrepancy shows clinicians should not rely solely on scans to assess treatment benefit before surgery.

There is no standard duration for systemic therapies like niragacestat. Clinicians often aim for 6-12 months, potentially extending to two years. The decision to stop is subjective and arbitrary, balancing treatment side effects against disease symptoms, highlighting the need for individualized approaches rather than fixed protocols.